Welichem Biotech Inc. is engaged in the discovery and development of novel small molecule therapeutics. Using its Symbiochem® technology platform, the Company has developed a robust pipeline of patent-protected compounds that target various diseases including inflammatory diseases and cancers.

Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders such as psoriasis and eczema. Four clinical studies were completed by the Company using WBI-1001 creams for the treatment of atopic dermatitis and psoriasis. In July 2012, the WBI-1001 technology was acquired by Stiefel, A Glaxo Group Limited (GSK) company, for further development, regulatory approval, and commercialization.

Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also synergistically increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia.

With its proven Symbiochem® technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is well positioned as a drug discovery and early stage drug development company developing novel small molecule therapies for unmet medical needs.